Skip to main content
. 2022 Dec 31;15(1):297. doi: 10.3390/cancers15010297

Table 1.

Baseline characteristics.

Characteristics mHSPC Total
(n = 20)		 a Tandem of 177Lu-PSMA and 225Ac-PSMA (n = 2) b 177Lu-PSMA
(n = 18)
Age, median (IQR)
PSA doubling time >6 months, n (%) 		69 (65.5–74)
5 (25%)		 76 (72–80)
1 (50%)		 68 (64.8–73.3)
4 (22.2%)
Previous treatments
Radical Prostatectomy, n(%)
PLND, n(%)
External beam radiotherapy, n (%)
Focal Cryotherapy, n(%)
Hormonal therapy, n (%)

  • ➢ LHRH agonist/antagonist

  • ➢ Bicalutamide

Previous chemotherapy (e.g., docetaxel), n (%)
15 (75%)
15 (75%)
15 (75%)
3 (15%)
8 (40%)
3 (15%)
7 (35%)
2 (10%)
1 (50%)
0
0
0
1 (50%)
1 (50%)
1 (50%)
1 (50%)
14 (77.8%)
15 (83.3%)
15 (83.3%)
3 (16.7%)
7 (38.9%)
2 (11.1%)
6 (33.3%)
1 (5.6%)
Site of disease on PSMA-PET/CT scan
* Low volume disease, n (%)
Hottest lesion, SUVmax, median (IQR)
Lymph nodes, n (%)
Bone, n (%)
Visceral, n (%)
16 (80%)
28.8 (11.5–36.3)
20 (100%)
6 (30%)
1 (5%)
0 (0%)
49.1 (44.3–53.8)
2 (100%)
1 (50%)
1 (50%)
16 (88.9%)
20.4 (11.1–32.4)
18 (100%)
5 (27.8%)
0 (0%)
PSMA radioligand therapy
Total number of PSMA-RLT cycles median (range)
Administered activity of 177Lu (GBq), per cycle median (IQR)
Administered activity of 225Ac (MBq) per cycle median (IQR)
2 (1–6)
6.2 (5.7–7.4)
4.2 (2.0–6.0)
6 (6–6)
7.2 (5.7–7.4)
4.2 (2.0–6.0)
2 (1–4)
6.1 (4.5–7.4)
0 (0–0)
Blood analysis Baseline
Hemoglobin (mmol/L), median (IQR)
Leukocytes (×109/L), median (IQR)
Thrombocytes (×109/L), median (IQR)
eGFR (mL/min), median (IQR)
Creatinine (µmol/L), median (IQR)
Alkaline phosphatase (U/L), median (IQR)
Lactate dehydrogenase (U/L), median (IQR)
PSA (µg/L), median (IQR)
8.9 (8.4–9.4)
5.7 (4.3–7.5)
232 (175–249)
79.9 (72–90)
81 (75–89)
63 (55.3–71.5)
196 (174–218)
5.9 (1.8–16.9)
9.5 (9.1–10)
6.1 (6–6.2)
204 (178–229)
77 (77–78)
85 (84–87)
85.0 (72–98)
204.5 (192–217)
146 (20–272)
8.8 (8.4–9.4)
5.3 (4.1–8.8)
238 (174–250)
84 (71–90)
80 (75–90)
59.5 (54.8–70)
195.5 (172–219)
5.1 (1.8–12.8)

a Patients were included if they received ≥ 1 cycle of tandem therapy, b patients were solely treated with 177Lu−PSMA. * Low volume disease was defined as max 5 metastases. Data for the tandem patients are given in mean (range).